Aspen Neuroscience logo

Aspen Neuroscience

Aspen Neuroscience develops autologous iPSC-derived cell replacement therapies for Parkinson’s disease and other CNS disorders.

3

Funding Rounds

$224.0m

Money raised

Overview

Aspen Neuroscience develops autologous iPSC-derived cell replacement therapies for Parkinson’s disease and other CNS disorders.

Funding

Funding series

Funding Series Analysis

The company Aspen Neuroscience has raised a total of $154m in funding over 3 rounds.

Key Insights:

  • Aspen Neuroscience Series B round, May 2022: $147.5m
  • Aspen Neuroscience Seed round, December 2019: $6.5m
  • Aspen Neuroscience Series A round Apr 1, 2020: $70m
Aspen Neuroscience logo
Aspen Neuroscience Series B round, May 2022 $147.5m
Aspen Neuroscience logo
Aspen Neuroscience Seed round, December 2019 $6.5m
Aspen Neuroscience logo
Aspen Neuroscience Series A round Apr 1, 2020 $70m